MIA Co-Medical Director opens SMR Congress in USA
21 November 2019
Professor Georgina Long, Co-Medical Director of Melanoma Institute Australia, has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
Professor Long is the first Australian and the first female President of SMR.
In her opening address, she summed up recent breakthroughs and advances in melanoma research and welcomed delegates from around the globe. This year's SMR Congress will cover a range of melanoma research and treatment related areas including the melanoma microenvironment, advances in early detection and prevention of melanoma, targeted and immunotherapies and advances in acral, mucosal and uveal melanoma. Women in STEM will also be a focus for the Congress.
Professor Long's opening address was followed by a Keynote Presentation on Cellular conversations that control cancer by University of California researcher, Professor Thea Tlsty, and the formal Welcome Reception. SMR continues into the weekend, with a packed program including a number of poster presentations from Melanoma Institute Australia researchers and students.
In sessions prior to the official opening, Co-Medical Director Professor Richard Scolyer led discussions at an International Melanoma Pathology Study Group workshop and the day-long International Melanoma Pathology Symposium.
The opening of SMR comes just a day after Professor Long and Professor Richard Scolyer were recognised as among the world’s most influential in their respective fields by being named in the prestigious Clarivate Analytics 2019 Highly Cited Researchers List.
Join us at the 2nd Melanoma Patients Australia webinar 'Psychological Health & Wellbeing'.
You're invited to be a C2S charity superstar, and together we can run over melanoma!
Join in the fun of the virtual event, and together we can run over melanoma!
Melanoma Institute Australia features prominently in the latest ‘Expertise in Melanoma’ world rankings, released by Expertscape.
Participate in our online survey and help us understand the support needs of melanoma patients and carers.
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.